DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Latanoprost; netarsudil dimesylateis the generic ingredient in one branded drug marketed by Aerie Pharms Inc and is included in one NDA. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Latanoprost; netarsudil dimesylate has fifty-seven patent family members in nine countries.
There are twenty drug master file entries for latanoprost; netarsudil dimesylate. One supplier is listed for this compound.
Pharmacology for latanoprost; netarsudil dimesylate
|Drug Class||Rho Kinase Inhibitor |
|Mechanism of Action||Rho Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for latanoprost; netarsudil dimesylate
|Country||Patent Number||Estimated Expiration|
|Japan||2014208681||⤷ Free Forever Trial|
|Hong Kong||1225733||⤷ Free Forever Trial|
|Japan||2019142953||⤷ Free Forever Trial|
|European Patent Office||2976080||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|3053913||2020/016||Ireland||⤷ Free Forever Trial||PRODUCT NAME: NETARSUDIL, OR AN ENANTIOMER, DIASTEREOMER, SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/19/1400 20191121|
|0364417||97C0128||France||⤷ Free Forever Trial||PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718|
|3053913||C202030018||Spain||⤷ Free Forever Trial||PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREOMERO, SAL O SOLVATO DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/19/1400; DATE OF AUTHORISATION: 20191119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1400; DATE OF FIRST AUTHORISATION IN EEA: 20191119|
|3053913||122020000016||Germany||⤷ Free Forever Trial||PRODUCT NAME: NETARSUDIL, ODER EIN ENANTIOMER, DIASTEREOMER, SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1400 20191119|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.